Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.020
+0.051 (5.30%)
At close: May 12, 2025, 4:00 PM
0.8199
-0.2000 (-19.62%)
After-hours: May 12, 2025, 7:59 PM EDT
Coherus BioSciences Employees
Coherus BioSciences had 228 employees as of December 31, 2024. The number of employees decreased by 78 or -25.49% compared to the previous year.
Employees
228
Change (1Y)
-78
Growth (1Y)
-25.49%
Revenue / Employee
$1,194,083
Profits / Employee
-$574,285
Market Cap
118.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CHRS News
- 4 hours ago - Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 days ago - Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - GlobeNewsWire
- 11 days ago - Coherus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - GlobeNewsWire
- 25 days ago - Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha
- 4 weeks ago - Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - GlobeNewsWire
- 6 weeks ago - Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire
- 2 months ago - Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript - Seeking Alpha